Influence of central alpha 1 inhibition in patients with essential hypertension.
CP-804-S is a substituted phenylbutylamine, known to lower arterial pressure in hypertensive animal models. In a double-blind, crossover study, 12 patients with essential hypertension receiving a constant sodium intake received placebo and CP-804-S, 150 mg daily. Standing (-5.5/-6.0 mm Hg) and supine (-8.5/-7.5 mm Hg) blood pressures and standing (-7.0 beats/min) and supine (-7.5 beats/min) pulse rates were significantly reduced by CP-804-S. Plasma renin activity (-0.41 ng/ml/hr) and plasma angiotensin I (-47 pg/ml) and angiotensin II (-3.0 pg/ml) levels decreased significantly. No significant changes were observed in plasma aldosterone or in the urinary excretion of aldosterone, kallikrein, and prostaglandin E2, F2 alpha, and F alpha metabolite.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007610:Kallikreins / Q000652:urine; D008297:Male; D008875:Middle Aged; D011187:Posture; D011412:Propanolamines / Q000627:therapeutic use*; D011453:Prostaglandins / Q000652:urine; D011674:Pulse / Q000187:drug effects; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects; D012084:Renin-Angiotensin System / Q000187:drug effects
D000317:Adrenergic alpha-Antagonists; D011412:Propanolamines; D011453:Prostaglandins; D011942:Receptors, Adrenergic, alpha; C037786:tibalosin; D007610:Kallikreins